Nicotinic Receptors, Amyloid-β, and Synaptic Failure in Alzheimer’s Disease

Dysfunctional cholinergic transmission is thought to underlie, at least in part, memory impairment and cognitive deficits in Alzheimer’s disease (AD). However, it is still unclear whether this is a consequence of the loss of cholinergic neurons and elimination of nicotinic acetycholine receptors (nAChRs) in AD brain or of a direct impact of molecular interactions of the amyloid-β (Aβ) peptide with nAChRs, leading to dysregulation of receptor function. This review examines recent progress in our understanding of the roles of nicotinic receptors in mechanisms of synaptic plasticity, molecular interactions of Aβ with nAChRs, and how Aβ-induced dysregulation of nicotinic receptor function may underlie synaptic failure in AD.

[1]  S. Ferreira,et al.  Structure and functions of the human amyloid precursor protein: The whole is more than the sum of its parts , 2007, Progress in Neurobiology.

[2]  J. Yakel,et al.  Inhibition of neuronal nicotinic acetylcholine receptor channels expressed in Xenopus oocytes by β-amyloid1–42 peptide , 2007, Journal of Molecular Neuroscience.

[3]  Yongling Zhu,et al.  Identification of Sequence Motifs That Target Neuronal Nicotinic Receptors to Dendrites and Axons , 2006, The Journal of Neuroscience.

[4]  D. Purpura,et al.  NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders , 2007, Nature Reviews Neuroscience.

[5]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[6]  A. Nordberg,et al.  Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists , 1992, Brain Research.

[7]  A. Fisher Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease , 2008, Neurotherapeutics.

[8]  T. Kihara,et al.  Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. , 2006, Biochemical and biophysical research communications.

[9]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[10]  S. Ferreira,et al.  Soluble Protein Oligomers as Emerging Toxins in Alzheimer′s and Other Amyloid Diseases , 2007 .

[11]  D. Muñoz-Torrero Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. , 2008, Current medicinal chemistry.

[12]  R. Rubey The Cholinesterase Inhibitors , 2003, Journal of psychiatric practice.

[13]  E. Perry,et al.  Expression of the α3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease , 1998 .

[14]  C. Herron,et al.  Nicotine enhances the depressive actions of A beta 1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. , 2003, Journal of neurophysiology.

[15]  T. Nabeshima,et al.  α7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in β-amyloid infused rats , 2006, Neuropharmacology.

[16]  N. Cutler,et al.  Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease , 1999, The Annals of pharmacotherapy.

[17]  K. Dineley Beta-amyloid peptide--nicotinic acetylcholine receptor interaction: the two faces of health and disease. , 2007, Frontiers in bioscience : a journal and virtual library.

[18]  Michael Frotscher,et al.  Cholinergic innervation of the rat hippocampus as revealed by choline acetyltransferase immunocytochemistry: A combined light and electron microscopic study , 1985, The Journal of comparative neurology.

[19]  A. Palmeri,et al.  Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus , 2008, The Journal of Neuroscience.

[20]  C. B. Davis,et al.  Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. , 2000, Journal of neurochemistry.

[21]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Sumikawa,et al.  Acute and chronic nicotine exposure differentially facilitate the induction of LTP , 1999, Brain Research.

[23]  C. Finch,et al.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  E. Albuquerque,et al.  Mammalian nicotinic acetylcholine receptors: from structure to function. , 2009, Physiological reviews.

[25]  D. Small,et al.  Cholinergic regulation of synaptic plasticity as a therapeutic target in Alzheimer's disease. , 2002, Journal of Alzheimer's disease : JAD.

[26]  J. David Sweatt,et al.  β-Amyloid Peptide Activates α7 Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes* , 2002, The Journal of Biological Chemistry.

[27]  George Perry,et al.  The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease , 2009, Journal of neurochemistry.

[28]  J. Jhamandas,et al.  β-Amyloid Peptide Activates Non-α7 Nicotinic Acetylcholine Receptors in Rat Basal Forebrain Neurons , 2003 .

[29]  J. Rusted,et al.  A comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine , 2005, Psychopharmacology.

[30]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.

[31]  F. Eusebi,et al.  Amyloid β1–42 peptide alters the gating of human and mouse α‐bungarotoxin‐sensitive nicotinic receptors , 2003, The Journal of physiology.

[32]  S. Matsuyama,et al.  Epibatidine induces long-term potentiation (LTP) via activation of alpha4beta2 nicotinic acetylcholine receptors (nAChRs) in vivo in the intact mouse dentate gyrus: both alpha7 and alpha4beta2 nAChRs essential to nicotinic LTP. , 2003, Journal of pharmacological sciences.

[33]  D. Chen,et al.  Distributions of nicotinic acetylcholine receptor α7 and β2 subunits on cultured hippocampal neurons , 1999, Neuroscience.

[34]  W. Klein,et al.  Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.

[35]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[36]  Y. He,et al.  α4β2 nicotinic acetylcholine receptors are required for the amyloid β protein-induced suppression of long-term potentiation in rat hippocampal CA1 region in vivo , 2008, Brain Research Bulletin.

[37]  S. Buckingham,et al.  Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes. , 2005, British journal of pharmacology.

[38]  J. Sweatt,et al.  beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. , 2002, The Journal of biological chemistry.

[39]  W. Klein,et al.  Amyloid beta oligomers induce impairment of neuronal insulin receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  A. Levey Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. J. Dougherty,et al.  β-Amyloid Regulation of Presynaptic Nicotinic Receptors in Rat Hippocampus and Neocortex , 2003, The Journal of Neuroscience.

[42]  T. Dunwiddie,et al.  alpha7 nicotinic acetylcholine receptors on GABAergic interneurons evoke dendritic and somatic inhibition of hippocampal neurons. , 2002, Journal of neurophysiology.

[43]  E. Marcello,et al.  Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. , 2008, European journal of pharmacology.

[44]  M. Bennett,et al.  The concept of long term potentiation of transmission at synapses , 2000, Progress in Neurobiology.

[45]  Robert A Nichols,et al.  Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 * nicotinic receptors. , 2007, Brain research.

[46]  W. Klein,et al.  Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  J. Stephenson,et al.  Chronic treatments with cholinoceptor drugs influence spatial learning in rats , 2005, Psychopharmacology.

[48]  J. Changeux,et al.  Role of Ca2+ Ions in Nicotinic Facilitation of GABA Release in Mouse Thalamus , 1997, The Journal of Neuroscience.

[49]  P. Livrea,et al.  Soluble β-Amyloid1-40 Induces NMDA-Dependent Degradation of Postsynaptic Density-95 at Glutamatergic Synapses , 2005, The Journal of Neuroscience.

[50]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[51]  R. Lukas,et al.  A Novel Nicotinic Acetylcholine Receptor Subtype in Basal Forebrain Cholinergic Neurons with High Sensitivity to Amyloid Peptides , 2009, The Journal of Neuroscience.

[52]  D. Ji,et al.  Timing and Location of Nicotinic Activity Enhances or Depresses Hippocampal Synaptic Plasticity , 2001, Neuron.

[53]  Su-Jane Wang,et al.  Facilitation of glutamate release by nicotine involves the activation of a Ca2+/calmodulin signaling pathway in rat prefrontal cortex nerve terminals , 2006, Synapse.

[54]  D. K. Berg,et al.  β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  L. Juliano,et al.  Amyloid-β Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/β-Catenin Signaling* , 2008, Journal of Biological Chemistry.

[56]  H. Eisenberg,et al.  Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer’s disease: histotopographical correlation with amyloid plaques and hyperphosphorylated‐tau protein , 1999, The European journal of neuroscience.

[57]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[58]  Y. Kuo,et al.  β-Amyloid Directly Inhibits Human α4β2-Nicotinic Acetylcholine Receptors Heterologously Expressed in Human SH-EP1 Cells* , 2004, Journal of Biological Chemistry.

[59]  R. Nichols,et al.  Dopamine release in prefrontal cortex in response to β-amyloid activation of α7∗ nicotinic receptors , 2007, Brain Research.

[60]  P. Greengard,et al.  Regulation of NMDA receptor trafficking by amyloid-beta. , 2005, Nature neuroscience.

[61]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[62]  Francesca Grassi,et al.  Amyloid β1–42 peptide alters the gating of human and mouse α‐bungarotoxin‐sensitive nicotinic receptors , 2003 .

[63]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[64]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[65]  J. A. Dani,et al.  Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. , 2007, Biochemical pharmacology.

[66]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[67]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[68]  D. Bertrand,et al.  Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. , 2007, Annual review of pharmacology and toxicology.

[69]  C. Mulle,et al.  Evidence for "preterminal" nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[70]  Piero Antuono,et al.  Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors , 2008, The Lancet Neurology.

[71]  D. Selkoe,et al.  The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Protein a , 1996 .

[72]  R. Gray,et al.  Hippocampal synaptic transmission enhanced by low concentrations of nicotine , 1996, Nature.

[73]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.

[74]  S. Matsuyama,et al.  Epibatidine Induces Long-Term Potentiation (LTP) via Activation of α4β2 Nicotinic Acetylcholine Receptors (nAChRs) In Vivo in the Intact Mouse Dentate Gyrus: Both α7 and α4β2 nAChRs Essential to Nicotinic LTP , 2003 .

[75]  Hoau Yan Wang,et al.  Amyloid Peptide Aβ1‐42 Binds Selectively and with Picomolar Affinity to α7 Nicotinic Acetylcholine Receptors , 2000 .

[76]  J. Jhamandas,et al.  Beta-amyloid peptide activates non-alpha7 nicotinic acetylcholine receptors in rat basal forebrain neurons. , 2003, Journal of neurophysiology.

[77]  A. Fine,et al.  Ultrastructural Distribution of the α7 Nicotinic Acetylcholine Receptor Subunit in Rat Hippocampus , 2001, The Journal of Neuroscience.

[78]  A. Nordberg,et al.  Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease , 1998, Drug safety.

[79]  P. Greengard,et al.  Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses , 2005, Neurobiology of Disease.

[80]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[81]  A. Nordberg,et al.  Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease , 2003, Neuroscience.

[82]  T. Nabeshima,et al.  alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. , 2006, Neuropharmacology.

[83]  D. Selkoe,et al.  The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. , 1996, Annals of the New York Academy of Sciences.

[84]  R. Anwyl,et al.  Nicotinic receptor‐mediated enhancement of long‐term potentiation involves activation of metabotropic glutamate receptors and ryanodine‐sensitive calcium stores in the dentate gyrus , 2006, The European journal of neuroscience.

[85]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[86]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[87]  R. Malinow,et al.  AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss , 2006, Neuron.

[88]  J. Buxbaum,et al.  Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. , 2000, European journal of pharmacology.

[89]  H. Ulrich,et al.  Peptide Blockers of the Inhibition of Neuronal Nicotinic Acetylcholine Receptors by Amyloid β* , 2005, Journal of Biological Chemistry.

[90]  J. Yakel,et al.  β-Amyloid1–42 Peptide Directly Modulates Nicotinic Receptors in the Rat Hippocampal Slice , 2001, The Journal of Neuroscience.

[91]  Marcela Colombres,et al.  Synaptotoxicity in Alzheimer's Disease: The Wnt Signaling Pathway as a Molecular Target , 2007, IUBMB life.

[92]  J. Patrick,et al.  Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[93]  J Patrick,et al.  Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat , 1989, The Journal of comparative neurology.

[94]  Jun Noguchi,et al.  Nicotinic cholinergic synaptic mechanisms in the ventral tegmental area contribute to nicotine addiction. , 2004, Learning & memory.

[95]  W. Klein Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer’s disease , 2006, Alzheimer's & Dementia.

[96]  T. Soderling,et al.  Regulatory mechanisms of AMPA receptors in synaptic plasticity , 2007, Nature Reviews Neuroscience.

[97]  A. Nordberg Effect of long‐term treatment with tacrine (THA) in Alzheimer's disease as visualized by PET , 1993, Acta neurologica Scandinavica. Supplementum.

[98]  John A. Dani,et al.  Differential Desensitization and Distribution of Nicotinic Acetylcholine Receptor Subtypes in Midbrain Dopamine Areas , 2003, The Journal of Neuroscience.

[99]  D. Price,et al.  Muscarinic and nicotinic cholinergic binding sites in alzheimer's disease cerebral cortex , 1987, Brain Research.

[100]  M. Swash,et al.  Possible biochemical basis of memory disorder in Alzheimer disease , 1978, Annals of neurology.

[101]  S. Buckingham,et al.  Subtype‐specific actions of β‐amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (α7, α4β2, α3β4) expressed in Xenopus laevis oocytes , 2005 .

[102]  H. Schröder,et al.  Nicotinic acetylcholine receptors in Alzheimer's disease. , 1999, Journal of Alzheimer's disease : JAD.